Eli Lilly & Co. struck a deal worth more than $1.1 billion with German biotech Seamless Therapeutics GmbH to develop gene therapies for hearing loss. Closely-held Seamless will design a type of enzyme ...
Eli Lilly is continuing a run of dealmaking to strengthen its genetic medicine offering by penning a pact with gene editing company Seamless Therapeutics. This morning’s deal with Seamless centers on ...
For Evangeline Lilly, the road to recovery doesn't have to be lonely. The Golden Globe-nominated actress, who has been navigating a traumatic brain injury, opened up about her recovery efforts in an ...
Evangeline Lily gave an update on her treatment plan after suffering a traumatic brain injury. The “Lost” star, 46, took to Instagram on Sunday, sharing how she was “restor[ing her] brain health.” “I ...
Jan 28 (Reuters) - U.S. drugmaker Eli Lilly (LLY.N), opens new tab signed an agreement worth up to $1.12 billion with Seamless Therapeutics, the Germany-based startup said on Wednesday, to develop and ...
Evangeline Lilly is opening up about her costly treatment following a traumatic brain injury. “I have spent a lot of money getting evaluated and getting targeted, expert advice on how to heal my brain ...
Top executives from drugmakers big and small told CNBC that the next phase of the obesity drug market will be defined by a broader range of treatment options and improved access for patients. CNBC ...
Evangeline Lilly Says She Has 'Spent a Lot of Money' to Find a 'Remedy' After Traumatic Brain Injury
The actress revealed her supplements in an Instagram video on Sunday, Jan. 25 Evangeline Lilly/Instagram Evangeline Lilly revealed she’s spent a large amount of money trying to find the right remedy ...
Eli Lilly is at the forefront of the GLP-1 weight loss drug market. The company's leading position is already being tested by Novo Nordisk's GLP-1 weight loss pill. Merck and Bristol Myers Squibb have ...
Eli Lilly and Co. has received the U.S. Food and Drug Administration’s breakthrough therapy designation for a drug in development to treat certain ovarian cancer patients. The Indianapolis-based ...
Eli Lilly's oral GLP-1 candidate, orforglipron, won't earn approval as fast as the company expected. Meanwhile, a notable competitor is making headway in this market. Even with this setback, Eli Lilly ...
NEW YORK, Jan 20 (Reuters) - Abivax Chief Executive Marc de Garidel dismissed as "noise" reports in the French press that pharmaceutical giant Eli Lilly (LLY.N), opens new tab may take over his ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results